LTR Pharma Signs US ROXUS Deal With Shed, Targets 150K Units

ROXUS is designed as a fast-acting intranasal spray for ED, with LTR reporting an onset of action in 10 minutes or less. Subject to clinical appropriateness, Shed will provide patients with a digital pathway to consultation and treatment through Mavrox and its own platform.

"Executing this definitive agreement with Shed is a major milestone in our US commercialisation strategy, and one we're genuinely excited about," LTR executive chair Lee Rodne said. "Combined with ROXUS's differentiated, rapid-onset profile, we believe this partnership gives US patients a genuinely differentiated treatment option and gives LTR Pharma a credible, scaled pathway into the US market."

Preparatory work is already underway. ROXUS is featured on the Mavrox platform and a patient waitlist has been established ahead of launch. "Mavrox will launch with ROXUS as its hero product, furthering our commitment to supporting its successful commercial launch," Shed and Mavrox chief executive officer Morley Baker said. "Our teams are eager to bring ROXUS to patients across the US alongside the LTR Pharma team."

LTR plans to update investors as the remaining launch conditions are satisfied. Timing remains dependent on completion of those requirements.